- Home
- RLTY vs INBX Comparison
RLTY vs INBX Comparison
Compare RLTY & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLTY
- INBX
- Stock Information
- Founded
- RLTY 2022
- INBX 2010
- Country
- RLTY United States
- INBX United States
- Employees
- RLTY N/A
- INBX N/A
- Industry
- RLTY Investment Managers
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- RLTY Finance
- INBX Health Care
- Exchange
- RLTY Nasdaq
- INBX Nasdaq
- Market Cap
- RLTY 256.9M
- INBX 218.9M
- IPO Year
- RLTY N/A
- INBX 2020
- Fundamental
- Price
- RLTY $14.82
- INBX $13.92
- Analyst Decision
- RLTY
- INBX Hold
- Analyst Count
- RLTY 0
- INBX 1
- Target Price
- RLTY N/A
- INBX N/A
- AVG Volume (30 Days)
- RLTY 86.7K
- INBX 71.1K
- Earning Date
- RLTY 01-01-0001
- INBX 11-14-2024
- Dividend Yield
- RLTY 9.35%
- INBX N/A
- EPS Growth
- RLTY N/A
- INBX N/A
- EPS
- RLTY N/A
- INBX 119.38
- Revenue
- RLTY N/A
- INBX $1,568,000.00
- Revenue This Year
- RLTY N/A
- INBX N/A
- Revenue Next Year
- RLTY N/A
- INBX N/A
- P/E Ratio
- RLTY N/A
- INBX $0.12
- Revenue Growth
- RLTY N/A
- INBX 19.24
- 52 Week Low
- RLTY $11.38
- INBX $10.80
- 52 Week High
- RLTY $14.60
- INBX $18.95
- Technical
- Relative Strength Index (RSI)
- RLTY 22.43
- INBX 38.33
- Support Level
- RLTY $14.56
- INBX $14.53
- Resistance Level
- RLTY $16.00
- INBX $15.24
- Average True Range (ATR)
- RLTY 0.26
- INBX 0.72
- MACD
- RLTY -0.14
- INBX -0.10
- Stochastic Oscillator
- RLTY 2.44
- INBX 19.16
About RLTY Cohen & Steers Real Estate Opportunities and Income Fund of Beneficial Interest
Cohen & Steers Real Estate Opportunities and Income Fund is an organized, non-diversified, closed-end management investment company. The Fund's primary investment objective is high current income. The Fund's secondary investment objective is capital appreciation.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.